1-5 of 5
Xuewen Ma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Ajai Chari, Cyrille Touzeau, Carolina Schinke, Monique C. Minnema, Jesus Berdeja, Albert Oriol, Niels WCJ Van De Donk, Paula Rodriguez Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Jo Caers, Leo Rasche, Amrita Y. Krishnan, Deeksha Vishwamitra, Xuewen Ma, Xiang Qin, Katharine S. Gries, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jenna D. Goldberg, Christoph Heuck, Jesús San-Miguel, Philippe Moreau
Journal: Blood
Blood (2022) 140 (Supplement 1): 384–387.
https://doi.org/10.1182/blood-2022-159707
Published: 2022
Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Cyrille Touzeau, Ajai Chari, Carolina Schinke, Monique C. Minnema, Jesus Berdeja, Albert Oriol, Niels WCJ Van De Donk, Paula Rodriguez Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Jo Caers, Leo Rasche, Amrita Y. Krishnan, Deeksha Vishwamitra, Xuewen Ma, Xiang Qin, Katharine S. Gries, Kelly Kato, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jenna D. Goldberg, Chris Heuck, Philippe Moreau, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4447–4449.
https://doi.org/10.1182/blood-2022-162555
Published: 2022
Journal Articles

MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Yaël C. Cohen, Philippe Moreau, Jaszianne Tolbert, Xiang Qin, Xuewen Ma, Diego Vieyra, Angelique Langlois, Christelle Courtoux, William Terry, Lixia Pei, Christoph Heuck, Peter Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 4418–4419.
https://doi.org/10.1182/blood-2022-162733
Published: 2022
Journal Articles

MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody

Shaji K Kumar, Alfred L. Garfall, Suzanne Trudel, Enrique M. Ocio, Emma Scott, Lin Huang, Xuewen Ma, Yunsi Olyslager, Payal Thakkar, Lixia Pei, Christoph Heuck, Evangelos Terpos
Journal: Blood
Blood (2022) 140 (Supplement 1): 7292–7293.
https://doi.org/10.1182/blood-2022-163260
Published: 2022
Journal Articles

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Amrita Y. Krishnan, Monique C. Minnema, Jesús G. Berdeja, Albert Oriol, Niels W.C.J. van de Donk, Paula Rodriguez-Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Raluca I. Verona, Xuewen Ma, Suzette Girgis, Shiyi Yang, Brandi W. Hilder, Jeffery Russell, Jenna D. Goldberg, Ajai Chari
Journal: Blood
Blood (2021) 138 (Supplement 1): 158.
https://doi.org/10.1182/blood-2021-146868
Published: 2021